These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27438146)

  • 1. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
    Ye H; Zhang X; Chen Y; Liu Q; Wei J
    Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.
    Guo J; Liu H; Zheng J
    Nucleic Acids Res; 2016 Jan; 44(D1):D1011-7. PubMed ID: 26516187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
    Srihari S; Singla J; Wong L; Ragan MA
    Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potential synthetic lethal genes to p53 using a computational biology approach.
    Wang X; Simon R
    BMC Med Genomics; 2013 Sep; 6():30. PubMed ID: 24025726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Literature-based translation from synthetic lethality screening into therapeutics targets: CD82 is a novel target for
    Yang HT; Chien MY; Chiang JH; Lin PC
    Comput Struct Biotechnol J; 2022; 20():5287-5295. PubMed ID: 36212540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSNK1E/CTNNB1 are synthetic lethal to TP53 in colorectal cancer and are markers for prognosis.
    Tiong KL; Chang KC; Yeh KT; Liu TY; Wu JH; Hsieh PH; Lin SH; Lai WY; Hsu YC; Chen JY; Chang JG; Shieh GS
    Neoplasia; 2014 May; 16(5):441-50. PubMed ID: 24947187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma.
    Szczurek E; Misra N; Vingron M
    Int J Cancer; 2013 Nov; 133(9):2123-32. PubMed ID: 23629686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Candidate Human Synthetic Lethal Interactions Through siRNA and Quantitative Imaging-Based Approaches.
    Jeusset LM; McManus KJ
    Methods Mol Biol; 2021; 2381():151-173. PubMed ID: 34590275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
    Wang X; Zhang Y; Han ZG; He KY
    Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Link synthetic lethality to drug sensitivity of cancer cells.
    Wang R; Han Y; Zhao Z; Yang F; Chen T; Zhou W; Wang X; Qi L; Zhao W; Guo Z; Gu Y
    Brief Bioinform; 2019 Jul; 20(4):1295-1307. PubMed ID: 29300844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.
    Liu L; Chen X; Hu C; Zhang D; Shao Z; Jin Q; Yang J; Xie H; Liu B; Hu M; Ke K
    Sci Rep; 2018 May; 8(1):8440. PubMed ID: 29855504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the landscape of synthetic lethal interactions in liver cancer.
    Yang C; Guo Y; Qian R; Huang Y; Zhang L; Wang J; Huang X; Liu Z; Qin W; Wang C; Chen H; Ma X; Zhang D
    Theranostics; 2021; 11(18):9038-9053. PubMed ID: 34522226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SL-scan identifies synthetic lethal interactions in cancer using metabolic networks.
    Zangene E; Marashi SA; Montazeri H
    Sci Rep; 2023 Sep; 13(1):15763. PubMed ID: 37737478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates.
    Zhang F; Wu M; Li XJ; Li XL; Kwoh CK; Zheng J
    J Bioinform Comput Biol; 2015 Jun; 13(3):1541002. PubMed ID: 25669329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
    Chang JG; Chen CC; Wu YY; Che TF; Huang YS; Yeh KT; Shieh GS; Yang PC
    Oncotarget; 2016 Nov; 7(45):73664-73680. PubMed ID: 27655641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response.
    Pinoli P; Srihari S; Wong L; Ceri S
    BMC Bioinformatics; 2021 May; 22(1):250. PubMed ID: 33992077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients.
    Markowska M; Budzinska MA; Coenen-Stass A; Kang S; Kizling E; Kolmus K; Koras K; Staub E; Szczurek E
    Sci Rep; 2023 Apr; 13(1):7049. PubMed ID: 37120674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of synthetic lethality by meta-analysis of genetic interactions, functions, and pathways in yeast and human cancer.
    Wu M; Li X; Zhang F; Li X; Kwoh CK; Zheng J
    Cancer Inform; 2014; 13(Suppl 3):71-80. PubMed ID: 25452682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
    Dando I; Cordani M; Donadelli M
    IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.